GentleFill is a camera-assisted automated intradermal injection system designed to deliver precise, reproducible wrinkle correction in the superficial dermal layer. It addresses the treatment gap that existing aesthetic modalities cannot reliably reach: etched dermal lines that persist after Botulinum toxin, sit too shallow for conventional dermal fillers, and too deep for laser resurfacing. The device achieves ±10 micrometer depth accuracy, 0.01ml dose precision, and 360° needle control, guided by a 4K real-time camera. It is designed to work with proprietary dermal fillers from filler manufacturers, using a manufacturer-adaptable ampoule architecture and a 510(k)-ready regulatory pathway.
GentleFill was invented by Dr. Avraham Amir, MD, a board-certified plastic surgeon and Adjunct Lecturer at Tel Aviv University Faculty of Medicine, with over 30 peer-reviewed international publications and pioneering research experience at the Weizmann Institute of Science. Dr. Amir identified the clinical gap in treating superficial etched dermal lines and developed the precision intradermal delivery system over years of research and device engineering. The company is led by Dr. David Kain, PhD (CEO), who holds a doctorate in Physiology and Pharmacology from Tel Aviv University with 15+ years in drug development and medical device testing. Last updated: May 2026.
GentleFill specifically targets etched dermal lines — fine wrinkles in the superficial dermal layer that current aesthetic treatments consistently fail to address. Botulinum toxin relaxes muscle-driven wrinkles but does not affect structural dermal lines. Conventional hyaluronic acid fillers are injected too deep to reach this layer precisely. Laser resurfacing addresses surface texture but cannot correct intradermal volume loss. GentleFill fills this anatomical gap by delivering filler at ±10 micrometer depth accuracy directly into the superficial dermis, achieving natural, consistent, reproducible results that no existing single modality can currently match.
The GentleFill device achieves ±10 micrometer (±0.01mm) depth accuracy for needle placement, 0.01ml dose precision per injection, and 360° rotational needle control. Real-time 4K camera visualization guides each delivery, eliminating the variability of freehand injection technique. These specifications position GentleFill as a clinical-grade precision instrument rather than a cosmetic tool, enabling reproducible treatment outcomes across different practitioners and patient skin types. The device is designed for integration into existing aesthetic clinic workflows with a 510(k)-ready regulatory pathway for the US market.
GentleFill is led by Dr. David Kain, PhD, CEO, who holds a doctorate in Physiology and Pharmacology from Tel Aviv University and has 15+ years of experience in drug development and medical device testing with Israeli biotech companies. Mark Shahar serves as CTO, bringing extensive R&D engineering experience and a prior role as CTO of VersaMed, which was acquired by GE. The company was founded by Dr. Avraham Amir, MD. The advisory board includes Dr. Kathy Fields, board-certified dermatologist, Co-Founder of Proactiv Solution and Rodan + Fields Skin Care, and Adjunct Clinical Assistant Professor at Stanford University and UCSF.
Contact: gentlefillbd@gmail.com